| 1 |
32095692 | Nicotinamide-Ponatinib Analogues as Potent Anti-CML and Anti-AML Compounds. | 2020 Feb 18 |
1 |
| 2 |
30705592 | Ponatinib: a novel multi-tyrosine kinase inhibitor against human malignancies. | 2019 |
1 |
| 3 |
29440177 | Ponatinib Shows Potent Antitumor Activity in Small Cell Carcinoma of the Ovary Hypercalcemic Type (SCCOHT) through Multikinase Inhibition. | 2018 Apr 15 |
3 |
| 4 |
30038711 | RET fusions observed in lung and colorectal cancers are sensitive to ponatinib. | 2018 Jul 3 |
3 |
| 5 |
28500237 | Resistance to RET-Inhibition in RET-Rearranged NSCLC Is Mediated By Reactivation of RAS/MAPK Signaling. | 2017 Aug |
3 |
| 6 |
28615362 | Drugging the catalytically inactive state of RET kinase in RET-rearranged tumors. | 2017 Jun 14 |
2 |
| 7 |
26377589 | Cabozantinib for the treatment of non-small cell lung cancer with KIF5B-RET fusion. An example of swift repositioning. | 2015 Dec |
1 |
| 8 |
25122427 | RET mutation and expression in small-cell lung cancer. | 2014 Sep |
1 |
| 9 |
23526464 | Ponatinib (AP24534) is a novel potent inhibitor of oncogenic RET mutants associated with thyroid cancer. | 2013 May |
11 |